M&A Deal Summary |
|
|---|---|
| Date | 2018-03-19 |
| Target | Mallinckrodt - Recothrom and Preveleak |
| Sector | Medical Products |
| Buyer(s) | Baxter International |
| Sellers(s) | Mallinckrodt |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1931 |
| Sector | Medical Products |
| Employees | 38,000 |
| Revenue | 10.6B USD (2024) |
Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 16 of 20 |
| Sector: Medical Products M&A | 9 of 12 |
| Type: Divestiture M&A Deals | 4 of 6 |
| Country: Ireland M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-12-15 |
Claris Injectables
Ahmedabad, India Claris Injectables Ltd. is a manufacturer and marketer of essential medicines across multiple delivery systems and segments, including anesthesia and analgesics; blood products; anti-infectives; critical care and nephrology. Its manufacturing facilities are registered with global regulatory agencies including the FDA and authorities in the UK, Australia, Brazil and Middle East. |
Buy | $625M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-10 |
Cheetah Medical
Newton Center, Massachusetts, United States Cheetah Medical, Inc. is a provider of non-invasive fluid management monitoring technologies, designed for use in critical care, operating room, and emergency department settings. Cheetah Medical, Inc. was founded in 2000 and is based in Newton Center, Massachusetts. |
Buy | $230M |
| Category | Company |
|---|---|
| Founded | 1867 |
| Sector | Life Science |
| Employees | 2,673 |
| Revenue | 2.2B USD (2021) |
Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 7 |
| Sector: Medical Products M&A | 3 of 4 |
| Type: Divestiture M&A Deals | 5 of 7 |
| Country: Ireland M&A | 3 of 4 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-12-26 |
Sucampo Pharmaceuticals
Bethesda, Maryland, United States Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. |
Buy | $1.2B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-18 |
Silence Therapeutics
London, United Kingdom Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Silence Therapeutics proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Silence Therapeutics was incorporated in 1994 and is based in London, United Kingdom. |
Buy | - |
